Electronics $24.5m
Expected value of the point-of-care testing (POCT) market by 2022, expanding at a CAGR of 5.7 %.
Yole
significantly more quickly, meaning outbreaks can be controlled more effectively. Some commercial devices for rapid detection of SARS-CoV-2 viruses have been successfully developed based on PCR or isothermal amplification.
American molecular diagnostics company Cepheid has developed a ‘sample-to-answer’ PCR system (Xpress SARS-CoV-2) with an integrated liquid handling cassette, making SARS-CoV-2 detection feasible in 45 minutes (30 minutes for a positive test) when used in tandem with its GeneXpert system. The combination provides results with a sensitivity of 98% and a specificity of 100%. In addition, two portable devices have been developed
Leader in Infrared Thermopiles and Gas Sensors for:
CO2
Capnography
to enable SARS-CoV-2 testing for home use. One is Lucira’s ‘all-in-one’ LAMP device, Lucira COVID- 19, which can detect SARS-CoV-2 in 30 minutes (11 minutes for a positive test). The other one is Visby Medical Covid-19 ‘all-in-one’ detection device developed based on continuous flow PCR and capable of SARS-CoV-2 detection in 30 minutes. Another, perhaps even more crucial, application has come into focus in the past year: mRNA vaccines are manufactured with microfluidics. Since mRNA is quickly degraded in the body by serum endonucleases and cannot even pass through the cell membrane due to charge separation, liquid nanoparticles (LNPs) are needed for intracellular transport. Due to their high biocompatibility, potent intracellular transfer, and protection against immune reactions and endonuclease degradation, they are particularly suitable as carriers for mRNA vaccines. Using microfluidic mixing processes, nanoparticles can be produced rapidly (in µs to ms) and with precisely defined properties (for example, size, homogeneity, higher encapsulation efficiencies, and higher reproducibility). Until now, an upscaling of this technique has been a major problem, however, a recent study led by University of Pennsylvania graduate research fellow Sarah J Shepherd introduced a simple, scalable, and parallelised microfluidic device containing an array of 128 parallel channels. With this, a maximum output 100 times greater than that of a single microfluidic channel can be achieved, and the output is directly scalable with the number of channels used.
Great potential
Microfluidic-based electronics have shown great potential in many applications, for example, bio-inspired devices, medical sensing systems, and wearables. During the Covid-19 pandemic, rapid and low- cost microfluidic electronic devices were developed for the detection of SARS- CoV-2 by researchers in the US and Taiwan. In contrast to conventional PCR for virus detection, the presence of the virus can be detected by means of distortions in the electrical signal. The system developed by the University of Florida and the National Yang Ming Chiao Tung University is based on a metal-oxide-semiconductor
78 Medical Device Developments /
www.nsmedicaldevices.com
www.heimannsensor.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170
